Brick & Kyle Associates’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Brick & Kyle Associates’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-400	Closed	-$6K	–	400
2017 Q1	$6K	Hold	400	–	–	﹤0.01%	373
2016 Q4	$6K	Hold	400	–	–	﹤0.01%	378
2016 Q3	$7K	Hold	400	–	–	0.01%	371
2016 Q2	$7K	Hold	400	–	–	0.01%	373
2016 Q1	$7K	Hold	400	–	–	0.01%	370
2015 Q4	$9K	Hold	400	–	–	0.01%	349
2015 Q3	$8K	Hold	400	–	–	0.01%	368
2015 Q2	$14K	Buy	+400	New	+$12.2K	0.01%	335

Other funds holding HZNP

SCM

Scopia Capital Management New York $112M AUM 48.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

BGIM

Brandywine Global Investment Management Philadelphia, Pennsylvania $14.9B AUM 20.41% 1-Year Est. Return

Brick & Kyle Associates's HZNP Position: Q2 2017 in Review

Brick & Kyle Associates sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q2 2017, closing a stake of 400 shares — an estimated $6K sold.

Brick & Kyle Associates first reported a position in HZNP in Q2 2015 and held it in 8 quarters. The position peaked at $14K in Q2 2015. 190 funds tracked by Wall St. Rank hold HZNP as of Q2 2017.

Brick & Kyle Associates reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q2 2017 after selling out during the quarter.
Brick & Kyle Associates sold 400 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q2 2017, an estimated $6K.
Brick & Kyle Associates first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2015 and held it in 8 quarters.
Brick & Kyle Associates's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $14K in Q2 2015.
190 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q2 2017.

Based on Brick & Kyle Associates's 13F filing for Q2 2017, filed 14 Aug 2017.